Deutsche Bank AG Has $71.23 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Deutsche Bank AG grew its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 0.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,693,108 shares of the biopharmaceutical company’s stock after purchasing an additional 4,137 shares during the quarter. Deutsche Bank AG owned about 1.83% of Ultragenyx Pharmaceutical worth $71,229,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Smartleaf Asset Management LLC boosted its stake in Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 493 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $35,000. Human Investing LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $42,000. Van ECK Associates Corp grew its stake in shares of Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 273 shares during the last quarter. Finally, Quarry LP bought a new position in Ultragenyx Pharmaceutical during the fourth quarter worth $84,000. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE opened at $36.09 on Tuesday. The business’s fifty day moving average price is $36.77 and its two-hundred day moving average price is $42.24. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $29.59 and a fifty-two week high of $60.37. The stock has a market capitalization of $3.41 billion, a price-to-earnings ratio of -5.69 and a beta of 0.34.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The firm had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm’s revenue for the quarter was up 28.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($2.03) EPS. Research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on RARE. Piper Sandler reduced their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a report on Monday, March 17th. Canaccord Genuity Group increased their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Morgan Stanley boosted their price target on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Wedbush reiterated a “neutral” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.93.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CAO Theodore Alan Huizenga sold 967 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $40,710.70. Following the sale, the chief accounting officer now owns 50,265 shares in the company, valued at approximately $2,116,156.50. This represents a 1.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Emil D. Kakkis sold 73,434 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $3,091,571.40. Following the completion of the transaction, the chief executive officer now directly owns 641,731 shares of the company’s stock, valued at $27,016,875.10. This represents a 10.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 125,405 shares of company stock valued at $5,285,169. Corporate insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.